1.Brenner H, Rothenbacher D, Arndt V. Epidemiology of stomach cancer. Cancer Epidemiology: Springer; 2009. p.467–77.
2.Crew KD, Neugut AI. Epidemiology of gastric cancer. World J. Gastroenterol. 2006;12:8.
3.World Cancer Report 2014. World Health Organization. 2014;Chapter 1.1.
4.Tan YK, Fielding JW. Early diagnosis of early gastric cancer. Eur J Gastroenterol Hepatol. 2006;18:821–9.
5.Sugimoto M, Yamaoka Y, Furuta T. Influence of interleukin polymorphisms on development of gastric cancer and peptic ulcer. World Journal of Gastroenterology. 2010;16:1188–200.
6.Cong AW, Sun YH, Shen ZB, Wang XF, Yin YQ, Fang Y, et al. Relationship between clinicopathologic factors and prognosis of patients with early gastric cancer. Chinese Journal of Digestive Surgery. 2018:338–40.
7.Pasechnikov V, Chukov S, Fedorov E, Kikuste I, Leja M. Gastric cancer:Prevention,screening and early diagnosis. World Journal of Gastroenterology. 2014;20:13842.
8.Zoalfaghari A, Aletaha N, Roushan N, Taslimi R, Foroutan H, Faridnia B. Accuracy of pepsinogens for early diagnosis of atrophic gastritis and gastric cancer in Iranian population. Medical Journal of the Islamic Republic of Iran. 2014;28:150-.
9.Xin L, Tang JH, Shen GR, Hao S, Yang HL. The value of PG Ⅰ,PG Ⅱ in diagnosis of atrophic gastritis and early gastric cancer. Clinical Journal of Medical Officers. 2012.
10.Chen J, Wei W, Tao Z, Ji J, Qian Q, Lu L, et al. Differential Expression of Phospholipase C Epsilon 1 Is Associated with Chronic Atrophic Gastritis and Gastric Cancer. Plos One. 2012;7:e47563-.
11.Tetsuya U, Stefano V, Hiroshi O, Masayoshi S, Cristian T, Simona R, et al. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncology. 2010;11:136–46.
12.Yang X, Pang YY, He RQ, Lin P, Cen JM, Yang H, et al. Diagnostic value of strand‐specific miRNA‐101‐3p and miRNA‐101‐5p for hepatocellular carcinoma and a bioinformatic analysis of their possible mechanism of action. Febs Open Bio. 2018;8:64–84.
13.Ma Y, Wei L, Pratt R, Trump DL, Johnson CS. Abstract 5095: 1,25D3 inhibits migration and invasion through miR–101–3p in human bladder cancer cells. Cancer Research. 2015;75:5095-.
14.Zhang XT, Zhang XY, Huang SY, Wang Q, Liu W. miRNA–101–3p inhibits proliferation and migration of gastric cancer cells by targeting EZH2. Chinese Journal of Pathophysiology. 2017.
15.Liu WJ, Xu Q, Sun LP, Dong QG, He CY, Yuan Y. Expression of serum let–7c, let–7i, and let–7f microRNA with its target gene, pepsinogen C, in gastric cancer and precancerous disease. Tumour Biol. 2015;36:3337–43.
16.Wu YF, Xu Q, He CY, Li Y, Liu JW, Deng N, et al. Association of Polymorphisms in three pri-miRNAs that Target Pepsinogen C with the Risk and Prognosis of Gastric Cancer. Scientific Reports. 2017;7:39528.
17.Livak KJ ST. Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2(-Delta Delta C(T))Method. METHODS. 2001;Dec;25(4):402–8.
18.Wu WKK, Lee CW, Cho CH, Fan D, Wu K, Yu J, et al. MicroRNA dysregulation in gastric cancer: a new player enters the game. Oncogene. 2010;29:5761–71.
19.Kupcinskas J, Wex T, Link A, Leja M, Bruzaite I, Steponaitiene R, et al. Gene polymorphisms of micrornas in Helicobacter pylori-induced high risk atrophic gastritis and gastric cancer. Plos One. 2014;9:e87467-.
20.Tchernitsa O, Kasajima AR, Kuban RJ, Ungethum U, Gyorffy B, Neumann U, et al. Systematic evaluation of the miRNA-ome and its downstream effects on mRNA expression identifies gastric cancer progression. Journal of Pathology. 2010;222:310–9.
21.Song YX, Yue ZY, Wang ZN, Xu YY, Luo Y, Xu HM, et al. MicroRNA–148b is frequently down-regulated in gastric cancer and acts as a tumor suppressor by inhibiting cell proliferation. Molecular Cancer. 2011;10:1.
22.Gao C, Zhang Z. Reduced microRNA–218 expression is associated with high nuclear factor kappa B activation in gastric cancer. Cancer. 2010;116:41–9.
23.Deng H, Guo Y, Song H, Xiao B, Sun W, Liu Z, et al. MicroRNA–195 and microRNA–378 mediate tumor growth suppression by epigenetical regulation in gastric cancer. Gene. 2013;518:351–9.
24.Sheng Y, Li J, Zou C, Wang S, Cao Y, Zhang J, et al. Downregulation of miR–101–3p by hepatitis B virus promotes proliferation and migration of hepatocellular carcinoma cells by targeting Rab5a. Archives of Virology. 2014;159:2397–410.
25.Cui Y, Zhang F, Zhu C, Geng L, Tian T, Liu H. Upregulated lncRNA SNHG1 contributes to progression of non-small cell lung cancer through inhibition of miR–101–3p and activation of Wnt/β-catenin signaling pathway. Oncotarget. 2017;8:17785–94.
26.Li C, Xiong D, Huang C, He R, Liang H, Pan D, et al. Clinical Value of miR–101–3p and Biological Analysis of its Prospective Targets in Breast Cancer: A Study Based on The Cancer Genome Atlas (TCGA) and Bioinformatics. Medical Science Monitor International Medical Journal of Experimental & Clinical Research. 2017;23:1857–71.
27.Ma Y, Luo W, Bunch BL, Pratt RN, Trump DL, Johnson CS. 1,25D3 differentially suppresses bladder cancer cell migration and invasion through the induction of miR–101–3p. Oncotarget. 2017;8:60080–93.
28.Xiao-Yu L, Zhi-Jian L, Hong H, Chen Z, Yun-Long W. MicroRNA–101–3p suppresses cell proliferation, invasion and enhances chemotherapeutic sensitivity in salivary gland adenoid cystic carcinoma by targeting Pim–1. Am J Cancer Res. 2015;5:3015–29.
29.Miki K. Gastric cancer screening using the serum pepsinogen test method. Gastric Cancer. 2006;9:245–53.
30.Zhao J, Zhu C, Li Z. Diagnostic value of serum pepsinogen, gastrin–17 and helicobacter pylori antibody for atrophic gastritis and gastric cancer. Chinese Journal of Gastroenterology. 2016.
31.Begum A, Baten MA, Begum Z, Ahsan MM, Rahman SF, Chowdhury F, et al. Role of Serum Pepsinogen I and II Ratio in Screening of Gastric Carcinoma. Mymensingh Medical Journal Mmj. 2017;26:628.
32.Watabe H, Mitsushima T, Yamaji Y, Okamoto M, Wada R, Kokubo T, et al. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. 2005;54:764–8.
33.Sembiring J, Sarumpaet K, Ganie RA. Diagnostic test pepsinogen I and combination with tumor marker CEA in gastric cancer. Iop Conference Series: Earth & Environmental Science; 2018.
34.Niu WW, Yang CC, Duan ZY, Huo XH, Gastroenterology DO. The diagnostic value of miRNA–92a combined with micro pepsinogen in gastric carcinoma. Journal of Hebei Medical University. 2017.
35.Wen-Jing L, Qian X, Li-Ping S, Qi-Guan D, Cai-Yun H, Yuan Y. Expression of serum let–7c, let–7i, and let–7f microRNA with its target gene, pepsinogen C, in gastric cancer and precancerous disease. Tumour Biol. 2015;36:3337–43.